Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2016 1
2017 1
2019 1
2020 2
2021 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.
Keeping S, Xu Y, Chen CI, Cope S, Mojebi A, Kuznik A, Konidaris G, Ayers D, Sasane M, Allen R, Huynh TM, Popoff E, Freeman M, Andria ML, Fury MG, Singh K, Stockfleth E, Challapalli A, Schmults CD. Keeping S, et al. Among authors: andria ml. Future Oncol. 2021 Feb;17(5):611-627. doi: 10.2217/fon-2020-0823. Epub 2020 Oct 14. Future Oncol. 2021. PMID: 33052055
A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (QUEST-AD): Baseline treatment patterns and unmet needs assessment.
Wei W, Ghorayeb E, Andria M, Walker V, Schnitzer J, Kennedy M, Chen Z, Belland A, White J, Silverberg JI. Wei W, et al. Among authors: andria m. Ann Allergy Asthma Immunol. 2019 Oct;123(4):381-388.e2. doi: 10.1016/j.anai.2019.07.008. Epub 2019 Jul 17. Ann Allergy Asthma Immunol. 2019. PMID: 31325566 Free article.
Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.
Van Cutsem E, Joulain F, Hoff PM, Mitchell E, Ruff P, Lakomý R, Prausová J, Moiseyenko VM, van Hazel G, Cunningham D, Arnold D, Schmoll HJ, Ten Tije AJ, McKendrick J, Kröning H, Humblet Y, Grávalos C, Le-Guennec S, Andria M, Dochy E, Vishwanath RL, Macarulla T, Tabernero J. Van Cutsem E, et al. Among authors: andria m. Target Oncol. 2016 Jun;11(3):383-400. doi: 10.1007/s11523-015-0402-9. Target Oncol. 2016. PMID: 26706237 Clinical Trial.